Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Update

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 27,938 shares, a growth of 1,415.9% from the December 15th total of 1,843 shares. Based on an average daily trading volume, of 84,214 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 84,214 shares, the days-to-cover ratio is currently 0.3 days.

Guided Therapeutics Stock Performance

Shares of GTHP traded down $0.07 during mid-day trading on Monday, hitting $0.36. 232,060 shares of the company traded hands, compared to its average volume of 41,972. Guided Therapeutics has a 1 year low of $0.06 and a 1 year high of $0.54. The stock has a 50-day moving average price of $0.30 and a two-hundred day moving average price of $0.27. The stock has a market cap of $31.40 million, a price-to-earnings ratio of -7.29 and a beta of 0.49.

Guided Therapeutics (OTCMKTS:GTHP) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.01) EPS for the quarter. The business had revenue of $0.06 million during the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.